GRI BIOPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 USD | -0.05% |
|
-18.55% | -93.58% |
| 04-16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
| 2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 3.7M 5.04M |
|---|---|---|---|---|---|
| Net income 2021 | -9M -12.28M | Net income 2022 | -7M -9.55M | EV / Sales 2021 | - |
| Net cash position 2021 | 7.34M 10.02M | Net cash position 2022 | 3.78M 5.16M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-4.2
x | P/E ratio 2022 |
-0.42
x | Employees | 2 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.05% | ||
| Current month | -93.58% | ||
| Current year | -93.58% |
1 year
0.42
8.89
3 years
0.42310.80
5 years
0.42310.80
10 years
0.42310.80
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.43 | -0.05% | 62,259 |
| 24-04-25 | 0.4302 | -1.65% | 25,078 |
| 24-04-24 | 0.4374 | -2.13% | 118,053 |
| 24-04-23 | 0.4469 | -2.85% | 143,359 |
| 24-04-22 | 0.46 | -12.86% | 394,531 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company's lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company's second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.
Sector
-
- Stock Market
- Equities
- GRI Stock
